Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million (52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of $1,150 Million (59% Growth Compared with Q3 2025) –
− Expands Target Enrollment in TRITON-CM Phase 3 Study of Nucresiran to 2,250 Patients; Study Design Continues to Support Expected ATTR-CM Launch by 2030 –
− Presented Positive Phase 1 Data for Brezosiran (ALN-HTT02) Demonstrating Robust Target Engagement and Encouraging Safety and Tolerability Profile in Patients with Huntington's Disease; Expect to Initiate Pivotal Study in 2027 –
− On Track to Achieve 2026 Financial Guidance – CAMBRIDGE, Mass., October 29, 2026 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2026, and reviewed recent business highlights.
“Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “As we continue through the final months of the year and plan for 2027, we remain laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis. In line with our goal to build durable leadership in TTR, the expanded enrollment target for TRITON-CM we are announcing today further positions nucresiran for success and strengthens our long-term position. Lastly, we believe the positive initial data for brezosiran in Huntington's disease both support a pathway to initiating a pivotal study in 2027 and reflect the potential of our RNAi platform to create meaningful value beyond our current portfolio.”
• Achieved global net product revenues for AMVUTTRA and ONPATTRO for the third quarter of $1,130 million and $20 million, respectively, together representing $1,150 million in total TTR net product revenues and 59% total TTR growth compared to Q3 2025.
◦ U.S. TTR net product revenues increased $99 million compared with Q2 2026 with the growth driven by an $81 million increase in demand, a $17 million inventory benefit, and a modest increase in net price as Q3 was aided by approximately $10 million in favorable gross-to-net adjustments.
◦ International TTR net product revenues increased $20 million compared with Q2 2026 driven primarily by ongoing ATTR-CM launches in Japan, Germany, and Italy as well as the timing of orders in partner markets.
• Presented new analyses from the HELIOS-B Phase 3 clinical trial of vutrisiran in patients with ATTR-CM at the European Society of Cardiology (ESC) Congress 2026. The findings further reinforce the clinical profile of vutrisiran across ATTR patient populations, treatment settings, and manifestations of disease, and vutrisiran's position as a first-line treatment option for ATTR-CM.
◦ A late-breaking prespecified subgroup analysis demonstrated that vutrisiran provided consistent clinical benefit across all-cause mortality and recurrent cardiovascular events in patients with or without tafamidis use at baseline. The results were simultaneously published in the Journal of the American College of Cardiology .
◦ Additional post-hoc analyses highlighted the positive impact of vutrisiran in addressing the multisystemic manifestations of ATTR-CM.
◦ A pooled analysis across four positive Phase 3 studies of vutrisiran and patisiran showed consistent treatment effect across sexes.
• Achieved global net product revenues for GIVLAARI and OXLUMO for the third quarter of $89 million and $53 million, respectively, together representing $142 million in total Rare net product revenues and 12% total Rare growth compared to Q3 2025.
, an investigational next-generation RNAi therapeutic, in patients with ATTR-CM. Nucresiran represents a key component of Alnylam's long-term growth strategy, with the potential to reinforce leadership in ATTR amyloidosis and expand the durability of the Company's TTR franchise.
◦ The Company is expanding target enrollment from 1,750 to approximately 2,250 patients. This expansion is enriched for patients with early disease who are expected to experience greatest benefit and ensures adequate study power under conservative estimates of outcome event rates.
◦ Given the rapid pace of enrollment and the event-driven nature of the study’s primary endpoint, the Company still expects to launch nucresiran, assuming positive data and regulatory approval, in ATTR-CM by 2030.
• Reported initial data at the European Huntington's Disease Network Clinical Research Congress from the Phase 1 clinical trial of
in patients with Huntington's disease. Brezosiran has the potential to establish a new growth platform beyond TTR and underscores Alnylam's strategy to broaden the application of RNAi therapeutics to new tissue types and therapeutic areas.
◦ Patients treated with single ascending intrathecal doses of brezosiran experienced robust, dose-dependent reductions of mutant huntingtin (mHTT) protein in cerebrospinal fluid (CSF), with target engagement demonstrated using two independent assays. A mean reduction of CSF mHTT of 60-64% from baseline was observed at month 3 in the highest dose group evaluated to date, with a maximum individual reduction of 83%. The observed durability of mHTT-lowering shows the potential for a twice-yearly dosing paradigm.
◦ An encouraging safety and tolerability profile has been observed to date, with no dose-dependent increases in CSF inflammatory markers, CSF neurofilament light chain (NfL) or brain ventricular volume.
◦ The Company plans to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment, to evaluate the ability of brezosiran to slow disease progression in adults with Huntington's disease. This program is being developed by Alnylam in collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron).
◦ Completed enrollment in the cAPPricorn-1 Phase 2 clinical trial in patients with CAA.
◦ Initiated a Phase 2 clinical trial in patients with Down syndrome-associated Alzheimer's disease.
◦ Shared additional Phase 1 data in early-onset Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. An analysis of safety data from single- and multiple-doses of mivelsiran showed no evidence of increased risk of amyloid-related imaging abnormality (ARIA) events. Results also showed robust, durable reductions in CSF soluble amyloid beta precursor protein (sAPPβ) and amyloid beta 42 (Aβ42), with up to 30 months of treatment exposure. The most common adverse events (AEs) were procedural pain and procedural headache, and no serious or severe AEs were deemed related to study drug.
, an investigational RNAi therapeutic targeting microtubule-associated protein tau (MAPT) for Alzheimer's disease and tauopathies.
Alnylam announced today that it will present two-year open-label extension results from the HELIOS-B Phase 3 clinical trial of
at the American Heart Association (AHA) Scientific Sessions 2026, being held November 6-9 in Chicago.
• The Company will also present results from an indirect treatment comparison of vutrisiran vs. acoramidis at the International Symposium of Amyloidosis (ISA), being held November 15-18 in Montevideo, Uruguay.
Alnylam also announced today that it will share Phase 1 healthy volunteer data for
, an investigational RNAi therapeutic in development for bleeding disorders, at the 2026 American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans.
in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of
in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027.
, an investigational RNAi therapeutic for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody- positive, is in November 2026. Cemdisiran is being advanced by Alnylam's collaborator, Regeneron. Assuming regulatory approval, Alnylam is eligible to receive tiered, double-digit royalties of up to 15 percent on global net sales of cemdisiran.
For an explanation of our use of non-GAAP financial measures, refer to the “Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure, see the tables at the end of this press release.
• Total net product revenues increased 52% and 53% at actual currency and at CER, respectively, during the three months ended September 30, 2026, compared to the same period in 2025. The increase was primarily due to growth from AMVUTTRA revenues driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., and growth from an increased number of patients treated with GIVLAARI, which was partially offset by a decreased number of patients treated with ONPATTRO.
• Net revenues from collaborations decreased during the three months ended September 30, 2026, as compared to the same period in 2025, primarily due to the recognition of $300.0 million of milestone revenue under our collaboration with Roche in September 2025 associated with the dosing of the first patient in the ZENITH Phase 3 clinical trial of zilebesiran.
• Royalty revenue increased during the three months ended September 30, 2026, as compared to the same period in 2025, due to increased volume and rate of royalties earned from global net sales of Leqvio by Novartis.
Cost of goods sold as a percentage of net product revenues increased during the three months ended September 30, 2026, as compared to the same period in 2025, primarily as a result of increased sales of AMVUTTRA and an associated increase in the blended royalty rate payable on net sales of AMVUTTRA.
• GAAP and non-GAAP R&D expenses for the three months ended September 30, 2026 increased as compared to the same period in 2025, primarily due to increased clinical trial expenses for the ZENITH Phase 3 clinical trial of zilebesiran in patients with uncontrolled hypertension, the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR-CM, and the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR-PN, along with increased spend on various preclinical programs.
• GAAP and non-GAAP SG&A expenses for the three months ended September 30, 2026 increased as compared to the same period in 2025, primarily due to increased sales and marketing investments associated with the ongoing global commercial launch of AMVUTTRA in ATTR-CM.
• Interest expense for the three months ended September 30, 2026 of $84 million included interest of $58 million attributed to the liability related to the sale of future Leqvio royalties and $23 million attributed to the liabilities related to vutrisiran and zilebesiran development funding.
• During the three months ended September 30, 2026, we recorded a benefit from income taxes of $1.9 billion, primarily related to the release of valuation allowances on certain U.S. federal and state deferred tax assets.
• Cash, cash equivalents and marketable securities were $3.6 billion as of September 30, 2026, as compared to $2.9 billion as of December 31, 2025, with the increase primarily driven by net cash inflows from operating activities.
• Net cash provided by operating activities for the three months ended September 30, 2026 included $35 million of payments associated with the liability related to the sale of future Leqvio royalties recorded to
interest expense, as well as $34 million of payments associated with the liabilities related to vutrisiran and zilebesiran development funding recorded to interest expense.
A reconciliation of our GAAP to non-GAAP financial results is included in the tables at the end of this press release.
Item FY 2026 Guidance Total TTR net product revenues (AMVUTTRA, $4,200 million - $4,500 million ONPATTRO)1 Total Rare net product revenues (GIVLAARI, $500 million - $600 million OXLUMO)1 Total net product revenues1 $4,700 million - $5,100 million Net product revenues growth vs. 2025 at currency 57% to 71% exchange rates as of June 30, 20261 Net product revenues growth vs. 2025 at constant 57% to 70% exchange rates2 Net revenues from collaborations and $575 million - $625 million royalties Non-GAAP R&D and SG&A expenses3 $2,700 million - $2,800 million 1Full-year 2026 guidance utilizing currency exchange rates as of June 30, 2026: 1 EUR = 1.14 USD and 1 USD = 162 JPY 2Representing growth calculated as if the exchange rates had remained unchanged from those used in 2025, which is a non-GAAP financial measure 3Excludes $330 million - $380 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses
This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and non-recurring gains or losses outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses, and loss related to covertible debt. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the loss related to convertible debt because the Company believes the item is a non-recurring transaction outside the ordinary course of the Company’s business.
Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period.
The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release.
Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026, at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
AMVUTTRA ® (vutrisiran) is a transthyretin (TTR) silencer that delivers rapid knockdown of TTR at the source to address the underlying cause of transthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. It is approved as a treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries, globally. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only silencer approved for the treatment of ATTR-CM and hATTR-PN. For more information about AMVUTTRA, including the full U.S. Prescribing Information, visit AMVUTTRA.com.
ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada for the treatment of adults with hATTR amyloidosis with polyneuropathy. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made. Reducing the pathogenic protein leads to a reduction in amyloid deposits in tissues. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com.
GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the European Union for the treatment of AHP in adults and adolescents aged 12 years and older. In the pivotal trial, GIVLAARI was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or intravenous hemin administration at home compared to placebo. GIVLAARI is Alnylam’s first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. GIVLAARI is administered via subcutaneous injection once monthly at a dose based on actual body weight and should be administered by a healthcare professional. GIVLAARI works by specifically reducing elevated levels of ALAS1 messenger RNA (mRNA), leading to reduction of toxins associated with attacks and other disease manifestations of AHP. For more information about GIVLAARI, including the full U.S. Prescribing Information, visit GIVLAARI.com.
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients and from the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. In the pivotal ILLUMINATE-A trial, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B pediatric Phase 3 trial, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C trial, OXLUMO resulted in substantial reductions in plasma oxalate in patients with advanced PH1. Across all three studies, injection site reactions (ISRs) were the most common drug-related adverse reaction. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, including the full U.S. Prescribing Information, visit OXLUMO.com.
Alnylam has licenses to Arbutus Biopharma lipid nanoparticle (LNP) intellectual property for use in RNAi therapeutic products using LNP technology.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel- prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit
This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding: Alnylam’s ability to leverage its commercial investments to expand the prescriber base for AMVUTTRA, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis; the potential for vutrisiran to be positioned as a first-line treatment option for ATTR-CM; the potential impact of any changes to the 340B Drug Pricing Program and payor utilization management policies such as step therapy requirements for AMVUTTRA or any of Alnylam’s other products; the potential for any of Alnylam’s programs to have transformative patient impact; the potential of Alnylam’s RNAi platform to create meaningful value beyond Alnylam’s current portfolio; the number of patients who will be enrolled in the TRITON-CM clinical trial of nucresiran in ATTR-CM and the characteristics of such patients; the potential for expanded enrollment in TRITON-CM to position nucresiran for success and to strengthen Alnylam’s longer-term position; the potential for nucresiran to reinforce Alnylam’s leadership in ATTR amyloidosis and to expand the durability of Alnylam’s TTR franchise; the potential for the TRITON-CM clinical trial to read out successfully; the potential for, and timing of, any commercial launch of nucresiran; the potential that Alnylam will commence a pivotal clinical trial of brezosiran and the timing of initiation of any such clinical trial; the potential for brezosiran to establish a new growth platform at Alnylam beyond TTR; the potential for Alnylam to succeed in its strategy to broaden the application of RNAi therapeutics to new tissue types and therapeutic areas; the timing of the announcement of clinical data from any of Alnylam’s clinical trials, including ALN-6400 and ALN-2232; the potential for cemdisiran to receive regulatory approval in the U.S. or any other jurisdiction, the timing of any such regulatory approval, and the potential for Alnylam to receive royalties from global net sales of cemdisiran; Alnylam’s ability to achieve the goals in its Alnylam 2030 strategy; and Alnylam’s projected commercial and financial performance, including the expected range for 2026 of TTR net product revenues, Rare net product revenues, total net product revenues, net revenues from collaborations and royalties, and non-GAAP R&D and SG&A expenses, including statements regarding where Alnylam’s actual results are expected to fall in relation to the expected range for any of these financial metrics. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully
execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s most recent periodic report (Quarterly Report on Form10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS -Unaudited Current assets: Cash and cash $ 1,754,340 $ 1,657,250 equivalents Marketable debt 1,832,915 1,251,234 securities Accounts 1,084,905 777,567 receivable, net Inventory 105,907 82,719 Prepaid expenses and other current 334,597 281,892 assets Total current 5,112,664 4,050,662 assets Property, plant 614,910 513,147 and equipment, net Operating lease right-of-use 177,950 194,916 assets Deferred tax 2,006,669 125,975 assets Restricted 22,172 22,170 investments Other assets 60,307 59,461 Total assets $ 7,994,672 $ 4,966,331 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 135,399 $ 115,721 Accrued expenses 1,236,289 1,080,197 Operating lease 46,083 45,518 liabilities Deferred revenue 11,669 4,845 Convertible debt 361,529 — Liabilities related to the sale of 272,037 220,068 future royalties and development funding Total current 2,063,006 1,466,349 liabilities Operating lease liabilities, net 203,294 225,087 of current portion Convertible debt, net of current 651,087 1,007,784 portion Liabilities related to the sale of future royalties 1,462,828 1,470,341 and development funding, net of current portion Other liabilities 10,605 7,594 Total liabilities 4,390,820 4,177,155 Stockholders' equity: Preferred stock, $0.01 par value per share, 5,000 shares authorized and no — — shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.01 par value per share, 250,000 shares authorized; 133,875 shares issued and outstanding as of 1,339 1,324 September 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 Additional paid-in 7,811,878 7,510,473 capital Accumulated other -44,661 -20,097 comprehensive loss Accumulated -4,164,704 -6,702,524 deficit Total stockholders' 3,603,852 789,176 equity Total liabilities and stockholders' $ 7,994,672 $ 4,966,331 equity
September 30, September 30, Three Months Ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── Reconciliation of GAAP to Non-GAAP Research and development expenses: GAAP Research and development $ 408,538 $ 358,814 expenses Less: Stock-based compensation -32,861 -48,725 expenses Non-GAAP Research and development $ 375,677 $ 310,089 expenses Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses:
GAAP Selling, general and $ 342,000 $ 322,076 administrative expenses Less: Stock-based compensation -46,257 -59,486 expenses Non-GAAP Selling, general and $ 295,743 $ 262,590 administrative expenses Reconciliation of GAAP to Non-GAAP Income (loss) from operations: GAAP Income from $ 345,798 $ 367,982 operations Add: Stock-based compensation 79,118 108,211 expenses Non-GAAP Operating $ 424,916 $ 476,193 income Reconciliation of GAAP to Non-GAAP Net income (loss): GAAP Net income $ 2,167,335 $ 292,683 Add: Stock-based compensation 79,118 108,211 expenses Add: Loss related — 39,146 to convertible debt Less: Income tax effect of GAAP to -4,543 -2,261 non-GAAP reconciling items Non-GAAP Net income $ 2,241,910 $ 437,779 Reconciliation of GAAP to Non-GAAP Net income (loss) per common share - basic: GAAP Net income (loss) per common $ 16.19 $ 2.23 share — basic Add: Stock-based compensation 0.59 0.82 expenses Add: Loss related — 0.30 to convertible debt Less: Income tax effect of GAAP to -0.03 -0.02 non-GAAP reconciling items Non-GAAP Net income per common share — $ 16.75 $ 3.33 basic Reconciliation of GAAP to Non-GAAP Net income (loss) per common share - diluted: GAAP Net income (loss) per common $ 15.72 $ 2.14 share - diluted Add: Stock-based compensation 0.57 0.79 expenses Add: Loss related $ — $ 0.29 to convertible debt Less: Income tax effect of GAAP to -0.03 -0.02 non-GAAP reconciling items Less: Impact to earnings per common share as a result of dilutive — -0.01 weighted-average common shares outstanding during the period* Non-GAAP Net income per common share - $ 16.26 $ 3.19 diluted* *Non-GAAP Net income per common share - diluted is calculated by dividing the non-GAAP net income by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. The dilutive weighted-average common shares outstanding for the three months ended September 30, 2026 and 2025would be 138,040 and 137,348 thousand shares, respectively.
Please note that the figures presented above may not sum exactly due to rounding
September 30, 2026 ──────────────────────────────────────────────────────────────────────── Three Months Ended AMVUTTRA net product revenue growth, as 65 % reported Add: Impact of foreign currency 1 translation AMVUTTRA net product revenue growth at 66 % constant currency ONPATTRO net product revenue growth, as -50 % reported Add: Impact of foreign currency — translation ONPATTRO net product revenue growth at -50 % constant currency Total TTR net product revenue growth, as 59 % reported Add: Impact of foreign currency 1 translation Total TTR net product revenue growth at 60 % constant currency GIVLAARI net product revenue growth, as 21 % reported Add: Impact of foreign currency 1 translation GIVLAARI net product revenue growth at 22 % constant currency OXLUMO net product revenue growth, as -1 % reported Add: Impact of foreign currency 1 translation OXLUMO net product revenue growth at — % constant currency Total Rare net product revenue growth, 12 % as reported Add: Impact of foreign currency 1 translation Total Rare net product revenue growth at 13 % constant currency Total net product revenue growth, as 52 % reported Add: Impact of foreign currency 1 translation Total net product revenue growth at 53 % constant currency Total revenue growth, as reported 17 % Add: Impact of foreign currency — translation Total revenue growth at constant 17 % currency
Full text with the tables
Exhibit 99.1
Contacts:
Alnylam Pharmaceuticals, Inc.
Bo Piela
(Media)
508-308-9783
Josh Brodsky
(Investors)
617-551-8276
Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and
Highlights Recent Period Progress
− Generated Third Quarter 2026 Global Net Product Revenues of $1,292 Million
(52% Growth Compared with Q3 2025), Driven Primarily by Total TTR Revenues of
$1,150 Million (59% Growth Compared with Q3 2025) –
− Expands Target Enrollment in TRITON-CM Phase 3 Study of Nucresiran to 2,250
Patients; Study Design Continues to Support Expected ATTR-CM Launch by 2030 –
− Presented Positive Phase 1 Data for Brezosiran (ALN-HTT02) Demonstrating
Robust Target Engagement and Encouraging Safety and Tolerability Profile in
Patients with Huntington's Disease; Expect to Initiate Pivotal Study in 2027 –
− On Track to Achieve 2026 Financial Guidance –
CAMBRIDGE, Mass., October 29, 2026 – Alnylam Pharmaceuticals, Inc. (Nasdaq:
ALNY), the leading RNAi therapeutics company, today reported its consolidated
financial results for the third quarter ended September 30, 2026, and reviewed
recent business highlights.
“Our third quarter results reflect the continued growth of our TTR franchise and
advancement of key programs with the potential for transformative patient
impact,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “As
we continue through the final months of the year and plan for 2027, we remain
laser focused on leveraging our commercial investments to expand the prescriber
base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis.
In line with our goal to build durable leadership in TTR, the expanded
enrollment target for TRITON-CM we are announcing today further positions
nucresiran for success and strengthens our long-term position. Lastly, we
believe the positive initial data for brezosiran in Huntington's disease both
support a pathway to initiating a pivotal study in 2027 and reflect the
potential of our RNAi platform to create meaningful value beyond our current
portfolio.”
Third Quarter 2026 and Recent Significant Business Highlights
Total TTR: AMVUTTRA
®
(vutrisiran) & ONPATTRO
®
(patisiran)
• Achieved global net product revenues for AMVUTTRA and ONPATTRO for the third
quarter of $1,130 million and $20 million, respectively, together representing
$1,150 million in total TTR net product revenues and 59% total TTR growth
compared to Q3 2025.
◦ U.S. TTR net product revenues increased $99 million compared with Q2 2026 with
the growth driven by an $81 million increase in demand, a $17 million inventory
benefit, and a modest increase in net price as Q3 was aided by approximately $10
million in favorable gross-to-net adjustments.
◦ International TTR net product revenues increased $20 million compared with Q2
2026 driven primarily by ongoing ATTR-CM launches in Japan, Germany, and Italy
as well as the timing of orders in partner markets.
• Presented new analyses from the HELIOS-B Phase 3 clinical trial of vutrisiran
in patients with ATTR-CM at the European Society of Cardiology (ESC) Congress
2026. The findings further reinforce the clinical profile of vutrisiran across
ATTR patient populations, treatment settings, and manifestations of disease, and
vutrisiran's position as a first-line treatment option for ATTR-CM.
◦ A late-breaking prespecified subgroup analysis demonstrated that vutrisiran
provided consistent clinical benefit across all-cause mortality and recurrent
cardiovascular events in patients with or without tafamidis use at baseline. The
results were simultaneously published in the Journal of the American College of
Cardiology .
◦ Additional post-hoc analyses highlighted the positive impact of vutrisiran in
addressing the multisystemic manifestations of ATTR-CM.
◦ A pooled analysis across four positive Phase 3 studies of vutrisiran and
patisiran showed consistent treatment effect across sexes.
Total Rare: GIVLAARI
®
(givosiran) & OXLUMO
®
(lumasiran)
• Achieved global net product revenues for GIVLAARI and OXLUMO for the third
quarter of $89 million and $53 million, respectively, together representing $142
million in total Rare net product revenues and 12% total Rare growth compared to
Q3 2025.
Key Pipeline Developments
• Today announced an update to the TRITON-CM Phase 3 study of
nucresiran
, an investigational next-generation RNAi therapeutic, in patients with ATTR-CM.
Nucresiran represents a key component of Alnylam's long-term growth strategy,
with the potential to reinforce leadership in ATTR amyloidosis and expand the
durability of the Company's TTR franchise.
◦ The Company is expanding target enrollment from 1,750 to approximately 2,250
patients. This expansion is enriched for patients with early disease who are
expected to experience greatest benefit and ensures adequate study power under
conservative estimates of outcome event rates.
◦ Given the rapid pace of enrollment and the event-driven nature of the study’s
primary endpoint, the Company still expects to launch nucresiran, assuming
positive data and regulatory approval, in ATTR-CM by 2030.
• Reported initial data at the European Huntington's Disease Network Clinical
Research Congress from the Phase 1 clinical trial of
brezosiran (ALN-HTT02)
in patients with Huntington's disease. Brezosiran has the potential to establish
a new growth platform beyond TTR and underscores Alnylam's strategy to broaden
the application of RNAi therapeutics to new tissue types and therapeutic areas.
◦ Patients treated with single ascending intrathecal doses of brezosiran
experienced robust, dose-dependent reductions of mutant huntingtin (mHTT)
protein in cerebrospinal fluid (CSF), with target engagement demonstrated using
two independent assays. A mean reduction of CSF mHTT of 60-64% from baseline was
observed at month 3 in the highest dose group evaluated to date, with a maximum
individual reduction of 83%. The observed durability of mHTT-lowering shows the
potential for a twice-yearly dosing paradigm.
◦ An encouraging safety and tolerability profile has been observed to date, with
no dose-dependent increases in CSF inflammatory markers, CSF neurofilament light
chain (NfL) or brain ventricular volume.
◦ The Company plans to initiate a placebo-controlled pivotal study in 2027,
pending regulatory alignment, to evaluate the ability of brezosiran to slow
disease progression in adults with Huntington's disease. This program is being
developed by Alnylam in collaboration with Regeneron Pharmaceuticals, Inc.
(Regeneron).
Additional Pipeline Progress
• Advanced
mivelsiran
, an investigational RNAi therapeutic targeting amyloid precursor protein (APP)
for the treatment of cerebral amyloid angiopathy (CAA) and Alzheimer’s disease.
◦ Completed enrollment in the cAPPricorn-1 Phase 2 clinical trial in patients
with CAA.
◦ Initiated a Phase 2 clinical trial in patients with Down syndrome-associated
Alzheimer's disease.
◦ Shared additional Phase 1 data in early-onset Alzheimer's disease at the
Alzheimer's Association International Conference (AAIC) 2026. An analysis of
safety data from single- and multiple-doses of mivelsiran showed no evidence of
increased risk of amyloid-related imaging abnormality (ARIA) events. Results
also showed robust, durable reductions in CSF soluble amyloid beta precursor
protein (sAPPβ) and amyloid beta 42 (Aβ42), with up to 30 months of treatment
exposure. The most common adverse events (AEs) were procedural pain and
procedural headache, and no serious or severe AEs were deemed related to study
drug.
• Presented preclinical data and Phase 1 design details at AAIC 2026 for
ALN-5288
, an investigational RNAi therapeutic targeting microtubule-associated protein
tau (MAPT) for Alzheimer's disease and tauopathies.
Key Upcoming Events
Alnylam announced today that it will present two-year open-label extension
results from the HELIOS-B Phase 3 clinical trial of
vutrisiran
at the American Heart Association (AHA) Scientific Sessions 2026, being held
November 6-9 in Chicago.
• The Company will also present results from an indirect treatment comparison of
vutrisiran vs. acoramidis at the International Symposium of Amyloidosis (ISA),
being held November 15-18 in Montevideo, Uruguay.
Alnylam also announced today that it will share Phase 1 healthy volunteer data
for
ALN-6400
, an investigational RNAi therapeutic in development for bleeding disorders, at
the 2026 American Society of Hematology (ASH) Annual Meeting and Exposition,
being held December 12-15 in New Orleans.
The Company now expects to announce clinical data from the Phase 2 trial of
ALN-6400
in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from
the Phase 1 trial of
ALN-2232
in obesity and weight management, in conjunction with its fourth quarter and
full year 2026 earnings call in February 2027.
The PDUFA target action date for
cemdisiran
, an investigational RNAi therapeutic for the treatment of adult patients with
generalized myasthenia gravis who are anti-acetylcholine receptor antibody-
positive, is in November 2026. Cemdisiran is being advanced by Alnylam's
collaborator, Regeneron. Assuming regulatory approval, Alnylam is eligible to
receive tiered, double-digit royalties of up to 15 percent on global net sales
of cemdisiran.
Third Quarter 2026 Financial Results
(In
thousand…
except Three
per share Months
amounts Ended
and September
percenta… 30, 2026 2025 % Change
──────────────────────────────────────────────────────────────────────────────
Total $ 1,458,086 $ 1,249,0… 17 %
revenues
GAAP
Income $ 345,798 $ 367,982 -6 %
from
operati…
Non-GAAP
Income $ 424,916 $ 476,193 -11 %
from
operati…
GAAP Net $ 2,167,335 $ 292,683 *
income
Non-GAAP
Net $ 2,241,910 $ 437,779 412 %
income
GAAP Net
income
per $ 16.19 $ 2.23 *
common
share —
basic
GAAP Net
income
per $ 15.72 $ 2.14 *
common
share —
diluted
Non-GAAP
Net
income
per $ 16.75 $ 3.33 403 %
common
share —
basic
Non-GAAP
Net
income
per $ 16.26 $ 3.19 410 %
common
share —
diluted
*
Indicat…
the
percent…
change
period
over
period
is
greater
than
500%
For an explanation of our use of non-GAAP financial measures, refer to the “Use
of Non-GAAP Financial Measures” section later in this press release and for a
reconciliation of each non-GAAP financial measure to the most comparable GAAP
measure, see the tables at the end of this press release.
Revenue Summary
(In
thou… Three
exce… Months
perc… Ended
Net Septe… %
prod… 30, % Change
reve… 2026 2025 Change at CER*
──────────────────────────────────────────────────────────────────────────────
AMVU… $ 1,130… $ 685,3… 65 % 66 %
ONPA… 19,596 39,075 -50 % -50 %
Total
TTR
net 1,149… 724,3… 59 % 60 %
prod…
reve…
GIVL… 89,487 73,874 21 % 22 %
OXLU… 52,500 52,830 -1 % — %
Total
Rare
net 141,9… 126,7… 12 % 13 %
prod…
reve…
Total
net 1,291… 851,0… 52 % 53 %
prod…
reve…
Net
reve…
from
coll…
Roche 39,107 326,6… -88 % -88 %
Rege… 32,334 22,542 43 % 43 %
Phar…
Other 35 2,596 -99 % -99 %
Total
net
reve… 71,476 351,7… -80 % -80 %
from
coll…
Roya… 94,664 46,202 105 % 105 %
reve…
Total $ 1,458… $ 1,249… 17 % 17 %
reve…
*
Chan…
at
cons…
exch…
rate…
or
CER,
repr…
grow…
calc…
as if
exch…
rates
had
rema…
unch…
from
those
used
duri…
the
three
mont…
ended
Sept…
30,
2025.
CER
is a
non-…
fina…
meas…
Total Net Product Revenues
• Total net product revenues increased 52% and 53% at actual currency and at
CER, respectively, during the three months ended September 30, 2026, compared to
the same period in 2025. The increase was primarily due to growth from AMVUTTRA
revenues driven by increased patient demand, mainly in patients with ATTR-CM in
the U.S., and growth from an increased number of patients treated with GIVLAARI,
which was partially offset by a decreased number of patients treated with
ONPATTRO.
Net Revenues from Collaborations
• Net revenues from collaborations decreased during the three months ended
September 30, 2026, as compared to the same period in 2025, primarily due to the
recognition of $300.0 million of milestone revenue under our collaboration with
Roche in September 2025 associated with the dosing of the first patient in the
ZENITH Phase 3 clinical trial of zilebesiran.
Royalty Revenue
• Royalty revenue increased during the three months ended September 30, 2026, as
compared to the same period in 2025, due to increased volume and rate of
royalties earned from global net sales of Leqvio by Novartis.
Operating Expense Summary
Three
(In Months
thousan… Ended
except Septemb… %
percent… 30, 2026 2025 Change
──────────────────────────────────────────────────────────────────────────────
Cost of
goods $ 361,750 $ 197,231 83 %
sold
% of
net 28.0 % 23.2 %
product
revenu…
Cost of
collab… $ — $ 2,923 -100 %
and
royalt…
GAAP
Resear…
and $ 408,538 $ 358,814 14 %
develo…
expens…
Non-GA…
Resear…
and $ 375,677 $ 310,089 21 %
develo…
expens…
GAAP
Sellin…
general $ 342,000 $ 322,076 6 %
and
admini…
expens…
Non-GA…
Sellin…
general $ 295,743 $ 262,590 13 %
and
admini…
expens…
Cost of Goods Sold
•
Cost of goods sold as a percentage of net product revenues increased during the
three months ended September 30, 2026, as compared to the same period in 2025,
primarily as a result of increased sales of AMVUTTRA and an associated increase
in the blended royalty rate payable on net sales of AMVUTTRA.
Research & Development (R&D) Expenses
• GAAP and non-GAAP R&D expenses for the three months ended September 30, 2026
increased as compared to the same period in 2025, primarily due to increased
clinical trial expenses for the ZENITH Phase 3 clinical trial of zilebesiran in
patients with uncontrolled hypertension, the TRITON-CM Phase 3 clinical trial of
nucresiran in patients with ATTR-CM, and the TRITON-PN Phase 3 clinical trial of
nucresiran in patients with hATTR-PN, along with increased spend on various
preclinical programs.
Selling, General & Administrative (SG&A) Expenses
• GAAP and non-GAAP SG&A expenses for the three months ended September 30, 2026
increased as compared to the same period in 2025, primarily due to increased
sales and marketing investments associated with the ongoing global commercial
launch of AMVUTTRA in ATTR-CM.
Other Financial Highlights
Interest expense
• Interest expense for the three months ended September 30, 2026 of $84 million
included interest of $58 million attributed to the liability related to the sale
of future Leqvio royalties and $23 million attributed to the liabilities related
to vutrisiran and zilebesiran development funding.
Benefit from income taxes
• During the three months ended September 30, 2026, we recorded a benefit from
income taxes of $1.9 billion, primarily related to the release of valuation
allowances on certain U.S. federal and state deferred tax assets.
Financial position
• Cash, cash equivalents and marketable securities were $3.6 billion as of
September 30, 2026, as compared to $2.9 billion as of December 31, 2025, with
the increase primarily driven by net cash inflows from operating activities.
• Net cash provided by operating activities for the three months ended September
30, 2026 included $35 million of payments associated with the liability related
to the sale of future Leqvio royalties recorded to
interest expense, as well as $34 million of payments associated with the
liabilities related to vutrisiran and zilebesiran development funding recorded
to interest expense.
A reconciliation of our GAAP to non-GAAP financial results is included in the
tables at the end of this press release.
2026 Financial Guidance
Full-year 2026 financial guidance is reiterated and consists of the following:
Item FY 2026 Guidance
Total TTR net product revenues (AMVUTTRA, $4,200 million - $4,500 million
ONPATTRO)1
Total Rare net product revenues
(GIVLAARI, $500 million - $600 million
OXLUMO)1
Total net product revenues1 $4,700 million - $5,100 million
Net product revenues growth vs. 2025 at
currency 57% to 71%
exchange rates as of June 30, 20261
Net product revenues growth vs. 2025 at
constant 57% to 70%
exchange rates2
Net revenues from collaborations and $575 million - $625 million
royalties
Non-GAAP R&D and SG&A expenses3 $2,700 million - $2,800 million
1Full-year 2026 guidance utilizing
currency
exchange rates as of June 30, 2026:
1 EUR = 1.14 USD and 1 USD = 162 JPY
2Representing growth calculated as if the
exchange
rates had remained unchanged from those
used in
2025, which is a non-GAAP financial
measure
3Excludes $330 million - $380 million of
stock-based compensation expense from
estimated
GAAP R&D and SG&A expenses
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including expenses
adjusted to exclude certain non-cash expenses and non-recurring gains or losses
outside the ordinary course of the Company’s business. These measures are not in
accordance with, or an alternative to, GAAP, and may be different from non-GAAP
financial measures used by other companies.
The items included in GAAP presentations but excluded for purposes of
determining non-GAAP financial measures for the periods presented in this press
release are stock-based compensation expenses, and loss related to covertible
debt. The Company has excluded the impact of stock-based compensation expense,
which may fluctuate from period to period based on factors including the
variability associated with performance-based grants for stock options and
restricted stock units and changes in the Company’s stock price, which impacts
the fair value of these awards. The Company has excluded the loss related to
convertible debt because the Company believes the item is a non-recurring
transaction outside the ordinary course of the Company’s business.
Percentage changes in revenue growth at CER are presented excluding the impact
of changes in foreign currency exchange rates for investors to understand the
underlying business performance. The current period’s foreign currency revenue
values are converted into U.S. dollars using the average exchange rates from the
prior period.
The Company believes the presentation of non-GAAP financial measures provides
useful information to management and investors regarding the Company’s financial
condition and results of operations. When GAAP financial measures are viewed in
conjunction with non-GAAP financial measures, investors are provided with a more
meaningful understanding of the Company’s ongoing operating performance and are
better able to compare the Company’s performance between periods. In addition,
these non-GAAP financial measures are among those indicators the Company uses as
a basis for evaluating performance, allocating resources and planning and
forecasting future periods. Non-GAAP financial measures are not intended to be
considered in isolation or as a substitute for GAAP financial measures. A
reconciliation between GAAP and non-GAAP measures is provided later in this
press release.
Conference Call Information
Management will provide an update on the Company and discuss third quarter 2026
results as well as expectations for the future via conference call on Thursday,
October 29, 2026, at 8:30 am ET. A live audio webcast of the call will be
available on the Investors section of the Company’s website at
www.alnylam.com/events. An archived webcast will be available on the Alnylam
website approximately two hours after the event.
About AMVUTTRA
®
(vutrisiran)
AMVUTTRA ® (vutrisiran) is a transthyretin (TTR) silencer that delivers rapid
knockdown of TTR at the source to address the underlying cause of transthyretin
amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly knocked down TTR in as
early as six weeks and decreased TTR levels by 87% with two and a half years of
treatment. It is approved as a treatment for the polyneuropathy of hereditary
transthyretin-mediated amyloidosis (hATTR-PN) in adults and for the
cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis
(ATTR-CM) in adults in various countries, globally. Administered quarterly via
subcutaneous injection, AMVUTTRA is the first and only silencer approved for the
treatment of ATTR-CM and hATTR-PN. For more information about AMVUTTRA,
including the full U.S. Prescribing Information, visit AMVUTTRA.com.
About ONPATTRO
®
(patisiran)
ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada
for the treatment of adults with hATTR amyloidosis with polyneuropathy. ONPATTRO
is also approved in the European Union, Switzerland and Brazil for the treatment
of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in
Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an
intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is
designed to target and silence TTR messenger RNA, thereby reducing the
production of TTR protein before it is made. Reducing the pathogenic protein
leads to a reduction in amyloid deposits in tissues. For more information about
ONPATTRO, including full Prescribing Information, visit ONPATTRO.com.
About GIVLAARI
®
(givosiran)
GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid
synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of
adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the
European Union for the treatment of AHP in adults and adolescents aged 12 years
and older. In the pivotal trial, GIVLAARI was shown to significantly reduce the
rate of porphyria attacks that required hospitalizations, urgent healthcare
visits or intravenous hemin administration at home compared to placebo. GIVLAARI
is Alnylam’s first commercially available therapeutic based on its Enhanced
Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and
durability. GIVLAARI is administered via subcutaneous injection once monthly at
a dose based on actual body weight and should be administered by a healthcare
professional. GIVLAARI works by specifically reducing elevated levels of ALAS1
messenger RNA (mRNA), leading to reduction of toxins associated with attacks and
other disease manifestations of AHP. For more information about GIVLAARI,
including the full U.S. Prescribing Information, visit GIVLAARI.com.
About OXLUMO
®
(lumasiran)
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1
(HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and
depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite
that directly contributes to the pathophysiology of PH1. OXLUMO utilizes
Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology,
which enables subcutaneous dosing with increased potency and durability and a
wide therapeutic index. OXLUMO has received regulatory approvals from the U.S.
Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria
type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult
patients and from the European Medicines Agency (EMA) for the treatment of PH1
in all age groups. In the pivotal ILLUMINATE-A trial, OXLUMO was shown to
significantly reduce levels of urinary oxalate relative to placebo, with the
majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B
pediatric Phase 3 trial, OXLUMO demonstrated an efficacy and safety profile
consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C trial, OXLUMO
resulted in substantial reductions in plasma oxalate in patients with advanced
PH1. Across all three studies, injection site reactions (ISRs) were the most
common drug-related adverse reaction. OXLUMO is administered via subcutaneous
injection once monthly for three months, then once quarterly beginning one month
after the last loading dose at a dose based on actual body weight. For patients
who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be
administered by a healthcare professional. For more information about OXLUMO,
including the full U.S. Prescribing Information, visit OXLUMO.com.
About LNP Technology
Alnylam has licenses to Arbutus Biopharma lipid nanoparticle (LNP) intellectual
property for use in RNAi therapeutic products using LNP technology.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that
represents one of the most promising and rapidly advancing frontiers in biology
and drug development today. Its discovery has been heralded as “a major
scientific breakthrough that happens once every decade or so,” and was
recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By
harnessing the natural biological process of RNAi occurring in our cells, a new
class of medicines known as RNAi therapeutics is now a reality. Small
interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s
RNAi therapeutic platform, function upstream of today’s medicines by potently
silencing messenger RNA (mRNA) – the genetic precursors – that encode for
disease-causing or disease pathway proteins, thus preventing them from being
made. This is a revolutionary approach with the potential to transform the care
of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the
pioneer of the RNA interference (RNAi) revolution. The Company is focused on
developing transformative therapies with the potential to prevent, halt, or
reverse disease. For more than two decades, Alnylam has advanced the Nobel-
prize-winning science of RNAi, delivering critical breakthroughs and six
approved medicines. Alnylam has medicines available in more than 70 countries
and a rapidly expanding and robust pipeline, in addition to consistently being
recognized as an exceptional workplace and socially responsible organization.
The Company is executing on its Alnylam 2030 strategy to accelerate innovation
and scale impact to transform human health. For more information, please visit
www.alnylam.com
or follow Alnylam on
X
,
LinkedIn
,
Facebook
,
Instagram
, or
YouTube
.
Alnylam Forward Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include statements regarding Alnylam’s expectations, beliefs, goals,
plans or prospects, including, without limitation, statements regarding:
Alnylam’s ability to leverage its commercial investments to expand the
prescriber base for AMVUTTRA, support access, and bring AMVUTTRA to more
patients with ATTR amyloidosis; the potential for vutrisiran to be positioned as
a first-line treatment option for ATTR-CM; the potential impact of any changes
to the 340B Drug Pricing Program and payor utilization management policies such
as step therapy requirements for AMVUTTRA or any of Alnylam’s other products;
the potential for any of Alnylam’s programs to have transformative patient
impact; the potential of Alnylam’s RNAi platform to create meaningful value
beyond Alnylam’s current portfolio; the number of patients who will be enrolled
in the TRITON-CM clinical trial of nucresiran in ATTR-CM and the characteristics
of such patients; the potential for expanded enrollment in TRITON-CM to position
nucresiran for success and to strengthen Alnylam’s longer-term position; the
potential for nucresiran to reinforce Alnylam’s leadership in ATTR amyloidosis
and to expand the durability of Alnylam’s TTR franchise; the potential for the
TRITON-CM clinical trial to read out successfully; the potential for, and timing
of, any commercial launch of nucresiran; the potential that Alnylam will
commence a pivotal clinical trial of brezosiran and the timing of initiation of
any such clinical trial; the potential for brezosiran to establish a new growth
platform at Alnylam beyond TTR; the potential for Alnylam to succeed in its
strategy to broaden the application of RNAi therapeutics to new tissue types and
therapeutic areas; the timing of the announcement of clinical data from any of
Alnylam’s clinical trials, including ALN-6400 and ALN-2232; the potential for
cemdisiran to receive regulatory approval in the U.S. or any other jurisdiction,
the timing of any such regulatory approval, and the potential for Alnylam to
receive royalties from global net sales of cemdisiran; Alnylam’s ability to
achieve the goals in its Alnylam 2030 strategy; and Alnylam’s projected
commercial and financial performance, including the expected range for 2026 of
TTR net product revenues, Rare net product revenues, total net product revenues,
net revenues from collaborations and royalties, and non-GAAP R&D and SG&A
expenses, including statements regarding where Alnylam’s actual results are
expected to fall in relation to the expected range for any of these financial
metrics. Actual results and future plans may differ materially from those
indicated by these forward-looking statements as a result of various important
risks, uncertainties and other factors, including, without limitation, risks and
uncertainties relating to: Alnylam’s ability to successfully
execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch,
market and sell Alnylam’s approved products globally, including AMVUTTRA;
Alnylam’s ability to discover and develop novel drug candidates and delivery
approaches and successfully demonstrate the efficacy and safety of its product
candidates; the pre-clinical and clinical results for Alnylam’s product
candidates; actions or advice of regulatory agencies and Alnylam’s ability to
obtain and maintain regulatory approval for its product candidates, as well as
favorable pricing and reimbursement; delays, interruptions or failures in the
manufacture and supply of Alnylam’s marketed products or its product candidates;
obtaining, maintaining and protecting intellectual property; Alnylam’s ability
to manage its growth and operating expenses through disciplined investment in
operations; Alnylam’s ability to maintain strategic business collaborations;
Alnylam’s dependence on third parties for the development and commercialization
of certain products; the outcome of litigation and government investigations;
the risk of future litigation and government investigations; and unexpected
expenditures; as well as those risks and uncertainties more fully discussed in
the “Risk Factors” filed with Alnylam’s most recent periodic report (Quarterly
Report on Form10-Q or Annual Report on Form 10-K) filed with the SEC and in its
other SEC filings. Alnylam explicitly disclaims any obligation, except to the
extent required by law, to update any forward-looking statements.
This release discusses investigational RNAi therapeutics and uses of previously
approved RNAi therapeutics in development and is not intended to convey
conclusions about efficacy or safety as to those investigational therapeutics or
uses. There is no guarantee that any investigational therapeutics or expanded
uses of commercial products will successfully complete clinical development or
gain health authority approval.
ALNYLAM PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS -Unaudited
Current assets:
Cash and cash $ 1,754,340 $ 1,657,250
equivalents
Marketable debt 1,832,915 1,251,234
securities
Accounts 1,084,905 777,567
receivable, net
Inventory 105,907 82,719
Prepaid expenses
and other current 334,597 281,892
assets
Total current 5,112,664 4,050,662
assets
Property, plant 614,910 513,147
and equipment, net
Operating lease
right-of-use 177,950 194,916
assets
Deferred tax 2,006,669 125,975
assets
Restricted 22,172 22,170
investments
Other assets 60,307 59,461
Total assets $ 7,994,672 $ 4,966,331
LIABILITIES AND
STOCKHOLDERS'
EQUITY
Current
liabilities:
Accounts payable $ 135,399 $ 115,721
Accrued expenses 1,236,289 1,080,197
Operating lease 46,083 45,518
liabilities
Deferred revenue 11,669 4,845
Convertible debt 361,529 —
Liabilities
related to the
sale of 272,037 220,068
future royalties
and development
funding
Total current 2,063,006 1,466,349
liabilities
Operating lease
liabilities, net 203,294 225,087
of
current portion
Convertible debt,
net of current 651,087 1,007,784
portion
Liabilities
related to the
sale of
future royalties 1,462,828 1,470,341
and development
funding, net of
current portion
Other liabilities 10,605 7,594
Total liabilities 4,390,820 4,177,155
Stockholders'
equity:
Preferred stock,
$0.01 par value
per
share, 5,000
shares authorized
and no — —
shares issued and
outstanding as of
September 30, 2026
and December 31,
2025
Common stock,
$0.01 par value
per share,
250,000 shares
authorized;
133,875
shares issued and
outstanding as of 1,339 1,324
September 30,
2026; 132,376
shares
issued and
outstanding as of
December
31, 2025
Additional paid-in 7,811,878 7,510,473
capital
Accumulated other -44,661 -20,097
comprehensive loss
Accumulated -4,164,704 -6,702,524
deficit
Total
stockholders' 3,603,852 789,176
equity
Total liabilities
and stockholders' $ 7,994,672 $ 4,966,331
equity
ALNYLAM PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Septem… Septem… Nine Septem… Septemb…
Months 30, 30, Months 30, 30,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
State…
of
Opera…
Reven…
Net
produ… $ 1,291,… $ 851,082 $ 3,500,… $ 1,991,8…
reven…
Net
reven… 71,476 351,742 200,716 512,423
from
colla…
Royal… 94,664 46,202 215,311 112,649
reven…
Total 1,458,… 1,249,… 3,916,… 2,616,9…
reven…
Opera…
costs
and
expen…
Cost
of 361,750 197,231 867,531 409,443
goods
sold
Cost
of
colla… — 2,923 3,792 4,705
and
royal…
Resea…
and 408,538 358,814 1,186,… 947,557
devel…
Selli…
gener… 342,000 322,076 1,012,… 885,339
and
admin…
Total
opera…
costs 1,112,… 881,044 3,070,… 2,247,0…
and
expen…
Income
from 345,798 367,982 845,875 369,860
opera…
Other
(expe…
incom…
Inter… -84,372 -67,462 -235,7… -187,227
expen…
Inter… 30,941 28,681 85,682 84,840
income
Loss
relat…
to — -39,146 — -39,146
conve…
debt
Other
income 3,443 -9,487 -579 8,564
(expe…
net
Total
other -49,988 -87,414 -150,6… -132,969
expen…
net
Income
before 295,810 280,568 695,269 236,891
income
taxes
Benef…
from
(prov… 1,871,… 12,115 1,842,… -34,687
for)
income
taxes
Net $ 2,167,… $ 292,683 $ 2,537,… $ 202,204
income
Net
income
per
common $ 16.19 $ 2.23 $ 19.02 $ 1.55
share
—
basic
Net
income
per
common $ 15.72 $ 2.14 $ 18.42 $ 1.51
share
—
dilut…
Weigh…
common
shares 133,828 131,447 133,444 130,590
—
basic
Weigh…
common
shares 138,040 137,348 138,184 134,146
—
dilut…
ALNYLAM PHARMACEUTICALS, INC.
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(In thousands, except per share amounts)
(Unaudited)
September 30, September 30,
Three Months Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Reconciliation of
GAAP to Non-GAAP
Research and
development
expenses:
GAAP Research and
development $ 408,538 $ 358,814
expenses
Less: Stock-based
compensation -32,861 -48,725
expenses
Non-GAAP Research
and development $ 375,677 $ 310,089
expenses
Reconciliation of
GAAP to Non-GAAP
Selling, general
and administrative
expenses:
GAAP Selling,
general and $ 342,000 $ 322,076
administrative
expenses
Less: Stock-based
compensation -46,257 -59,486
expenses
Non-GAAP Selling,
general and $ 295,743 $ 262,590
administrative
expenses
Reconciliation of
GAAP to Non-GAAP
Income (loss) from
operations:
GAAP Income from $ 345,798 $ 367,982
operations
Add: Stock-based
compensation 79,118 108,211
expenses
Non-GAAP Operating $ 424,916 $ 476,193
income
Reconciliation of
GAAP to Non-GAAP
Net
income (loss):
GAAP Net income $ 2,167,335 $ 292,683
Add: Stock-based
compensation 79,118 108,211
expenses
Add: Loss related — 39,146
to convertible debt
Less: Income tax
effect of GAAP to -4,543 -2,261
non-GAAP
reconciling items
Non-GAAP Net income $ 2,241,910 $ 437,779
Reconciliation of
GAAP to Non-GAAP
Net
income (loss) per
common share -
basic:
GAAP Net income
(loss) per common $ 16.19 $ 2.23
share
— basic
Add: Stock-based
compensation 0.59 0.82
expenses
Add: Loss related — 0.30
to convertible debt
Less: Income tax
effect of GAAP to -0.03 -0.02
non-GAAP
reconciling items
Non-GAAP Net income
per common share — $ 16.75 $ 3.33
basic
Reconciliation of
GAAP to Non-GAAP
Net
income (loss) per
common share -
diluted:
GAAP Net income
(loss) per common $ 15.72 $ 2.14
share
- diluted
Add: Stock-based
compensation 0.57 0.79
expenses
Add: Loss related $ — $ 0.29
to convertible debt
Less: Income tax
effect of GAAP to -0.03 -0.02
non-GAAP
reconciling items
Less: Impact to
earnings per common
share as a result
of dilutive — -0.01
weighted-average
common shares
outstanding during
the period*
Non-GAAP Net income
per common share - $ 16.26 $ 3.19
diluted*
*Non-GAAP Net
income per common
share -
diluted is
calculated by
dividing the
non-GAAP net income
by the
weighted-average
number of common
shares
and dilutive
potential common
share
equivalents
outstanding during
the
period. The
dilutive
weighted-average
common shares
outstanding for the
three
months ended
September 30, 2026
and
2025would be
138,040 and 137,348
thousand shares,
respectively.
Please note that the figures presented above may not sum exactly due to rounding
ALNYLAM PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP
PRODUCT REVENUE GROWTH AT CONSTANT CURRENCY
(Unaudited)
September 30, 2026
────────────────────────────────────────────────────────────────────────
Three Months Ended
AMVUTTRA net product revenue growth, as 65 %
reported
Add: Impact of foreign currency 1
translation
AMVUTTRA net product revenue growth at 66 %
constant currency
ONPATTRO net product revenue growth, as -50 %
reported
Add: Impact of foreign currency —
translation
ONPATTRO net product revenue growth at -50 %
constant currency
Total TTR net product revenue growth, as 59 %
reported
Add: Impact of foreign currency 1
translation
Total TTR net product revenue growth at 60 %
constant currency
GIVLAARI net product revenue growth, as 21 %
reported
Add: Impact of foreign currency 1
translation
GIVLAARI net product revenue growth at 22 %
constant currency
OXLUMO net product revenue growth, as -1 %
reported
Add: Impact of foreign currency 1
translation
OXLUMO net product revenue growth at — %
constant currency
Total Rare net product revenue growth, 12 %
as reported
Add: Impact of foreign currency 1
translation
Total Rare net product revenue growth at 13 %
constant currency
Total net product revenue growth, as 52 %
reported
Add: Impact of foreign currency 1
translation
Total net product revenue growth at 53 %
constant currency
Total revenue growth, as reported 17 %
Add: Impact of foreign currency —
translation
Total revenue growth at constant 17 %
currency